PDCD1 and melanoma: Given the transcriptional features of T cells reactivating in the presence of anti-PD1, we interrogated to what extent strong TCR signatures are evident in human datasets of melanoma patients undergoing PD1 pathway therapy (Gide et al., 2019; Riaz et al., 2017).